Last reviewed · How we verify
HB0025
HB0025 is a small molecule that targets the SGLT2 receptor.
HB0025 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | HB0025 |
|---|---|
| Also known as | Recombinant Humanized Anti-PD-L1 Monoclonal Antibody-VEGFR1 Fusion Protein, Recombinant humanized anti-programmed cell death-ligand 1（Anti-PD-L1） monoclonal antibody-VEGFR1 fusion protein |
| Sponsor | Huabo Biopharm Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, HB0025 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (PHASE3)
- A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC (PHASE2)
- Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (PHASE3)
- A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor (PHASE1, PHASE2)
- A Study of HB0025 Injection in Patients With Advanced Renal Cancer (PHASE2)
- A Study of Injection HB0025 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB0025 CI brief — competitive landscape report
- HB0025 updates RSS · CI watch RSS
- Huabo Biopharm Co., Ltd. portfolio CI